

# Tatiana do Nascimento Pedrosa

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7185436/publications.pdf>

Version: 2024-02-01

25  
papers

567  
citations

758635

12  
h-index

676716

22  
g-index

27  
all docs

27  
docs citations

27  
times ranked

881  
citing authors

#	ARTICLE	IF	CITATIONS
1	Immunogenicity and safety of the CoronaVac inactivated vaccine in patients with autoimmune rheumatic diseases: a phase 4 trial. <i>Nature Medicine</i> , 2021, 27, 1744-1751.	15.2	148
2	A new reconstructed human epidermis for in vitro skin irritation testing. <i>Toxicology in Vitro</i> , 2017, 42, 31-37.	1.1	51
3	Two-week methotrexate discontinuation in patients with rheumatoid arthritis vaccinated with inactivated SARS-CoV-2 vaccine: a randomised clinical trial. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 889-897.	0.5	42
4	Safety and immunogenicity of CoronaVac in people living with HIV: a prospective cohort study. <i>Lancet HIV</i> , 2022, 9, e323-e331.	2.1	36
5	In vitro safety and efficacy evaluations of a complex botanical mixture of <i>Eugenia dysenterica</i> DC. (Myrtaceae): Prospects for developing a new dermocosmetic product. <i>Toxicology in Vitro</i> , 2017, 45, 397-408.	1.1	30
6	Anti-wrinkle and anti-whitening effects of <i>Jucã</i> ( <i>Libidibia ferrea</i> Mart.) extracts. <i>Archives of Dermatological Research</i> , 2016, 308, 643-654.	1.1	29
7	Impact of Distinct Therapies on Antibody Response to SARS-CoV-2 Vaccine in Systemic Lupus Erythematosus. <i>Arthritis Care and Research</i> , 2022, 74, 562-571.	1.5	25
8	Immunogenicity and safety of two doses of the CoronaVac SARS-CoV-2 vaccine in SARS-CoV-2 seropositive and seronegative patients with autoimmune rheumatic diseases in Brazil: a subgroup analysis of a phase 4 prospective study. <i>Lancet Rheumatology</i> , 2022, 4, e113-e124.	2.2	24
9	Ozone Gas as a Benign Sterilization Treatment for PLGA Nanofiber Scaffolds. <i>Tissue Engineering - Part C: Methods</i> , 2016, 22, 338-347.	1.1	21
10	Understanding the dynamics of hydroxychloroquine blood levels in lupus nephritis. <i>Lupus</i> , 2020, 29, 560-568.	0.8	18
11	Methyl- $\beta$ -cyclodextrin treatment combined to incubation with interleukin-4 reproduces major features of atopic dermatitis in a 3D-culture model. <i>Archives of Dermatological Research</i> , 2017, 309, 63-69.	1.1	16
12	Distinct impact of DMARD combination and monotherapy in immunogenicity of an inactivated SARS-CoV-2 vaccine in rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 710-719.	0.5	16
13	The influence of obesity on hydroxychloroquine blood levels in lupus nephritis patients. <i>Lupus</i> , 2021, 30, 554-559.	0.8	14
14	Systemic autoimmune myopathies: a prospective phase 4 controlled trial of an inactivated virus vaccine against SARS-CoV-2. <i>Rheumatology</i> , 2022, 61, 3351-3361.	0.9	13
15	Immunogenicity, safety, and antiphospholipid antibodies after SARS-CoV-2 vaccine in patients with primary antiphospholipid syndrome. <i>Lupus</i> , 2022, 31, 974-984.	0.8	13
16	Atividades biológicas dos óleos essenciais de <i>Endlicheria citriodora</i> , uma lauraceae rica em geranato de metila. <i>Química Nova</i> , 2013, 36, 826-830.	0.3	12
17	Estudo farmacognóstico e atividade in vitro sobre a coagulação sanguínea e agregação plaquetária das folhas de <i>Passiflora nitida</i> Kunth (Passifloraceae). <i>Acta Amazonica</i> , 2010, 40, 199-206.	0.3	9
18	Hydroxychloroquine blood levels predicts flare in childhood-onset lupus nephritis. <i>Lupus</i> , 2022, 31, 97-104.	0.8	9

#	ARTICLE	IF	CITATIONS
19	SARS-CoV-2 vaccine in patients with systemic sclerosis: impact of disease subtype and therapy. <i>Rheumatology</i> , 2022, 61, SI169-SI174.	0.9	9
20	Hydroxychloroquine blood levels in stable lupus nephritis under low dose (2-3 mg/kg/day): 12-month prospective randomized controlled trial. <i>Clinical Rheumatology</i> , 2021, 40, 2745-2751.	1.0	8
21	Inactivated SARS-CoV-2 vaccine in primary Sjögren's syndrome: humoral response, safety, and effects on disease activity. <i>Clinical Rheumatology</i> , 2022, 41, 2079-2089.	1.0	7
22	Lupus nephritis-related issues during COVID-19 pandemic quarantine. <i>Lupus</i> , 2020, 29, 1978-1980.	0.8	5
23	Immunogenicity and safety of primary fractional-dose yellow fever vaccine in autoimmune rheumatic diseases. <i>PLoS Neglected Tropical Diseases</i> , 2021, 15, e0010002.	1.3	5
24	One-year prospective nerve conduction study of thalidomide neuropathy in lupus erythematosus: Incidence, coasting effect and drug plasma levels. <i>Lupus</i> , 2021, 30, 956-964.	0.8	3
25	Influenza A/Singapore (H3N2) component vaccine in systemic lupus erythematosus: A distinct pattern of immunogenicity. <i>Lupus</i> , 2021, 30, 1915-1922.	0.8	3